Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: Coexpression with EGFR and EGFR ligands

Cancer Science

Volumn 100, Issue 4, 2009, Pages 654-662

  Nakagawa, Motomichi ^a,d   Nabeshima, Kazuki ^a   Asano, Shigeyuki ^a   Hamasaki, Makoto ^a   Uesugi, Noriko ^b   Tani, Hiroki ^c   Yamashita, Yuichi ^d   Iwasaki, Hiroshi ^a  

^a FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^b Iwaki Kyoritsu General Hospital   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d Hakuaikai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM10 PROTEIN; ADAM17 PROTEIN; ADAM9 PROTEIN; AMPHIREGULIN; BETACELLULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; GELATINASE A; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; METALLOPROTEINASE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; DISINTEGRIN; LIGAND; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERSTITIAL CELL OF CAJAL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; GENETICS; MIDDLE AGED;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; DISINTEGRINS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; UP-REGULATION;

EID: 67449099151     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01089.x     Document Type: Article

References (46)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors -definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
2. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65.
3. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Laboratory Med 2006; 130: 1466-78.
5. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
6. Hirota S, Ohashi A, Nishida T et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-7.
7. van Oosterom AT, Judson IR, Verweij J et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 (Suppl 5): S83-7.
8. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-64.
9. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90.
10. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-74.
11. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98: 621-8.
12. Moss ML, Jin SL, Milla ME et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385: 733-6.
13. Sunnarborg SW, Hinkle CL, Stevenson M et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002; 277: 12838-45.
14. Hinkle CL, Sunnarborg SW, Loiselle D et al. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: The juxtamembrane stalk determines cleavage efficiency. J Biol Chem 2004; 279: 24179-88.
15. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-8.
16. Umata T, Hirata M, Takahashi T et al. A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2001; 276: 30475-82.
17. Brown CL, Meise KS, Plowman GD, Coffey RJ, Dempsey PJ. Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor. Release of a predominant N-glycosylated 43-kDa soluble form. J Biol Chem 1998; 273: 17258-68.
18. McCulloch DR, Harvey M, Herington AC. The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol Cell Endocrinol 2000; 167: 11-21.
19. Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA, Crabtree JE. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 2002; 185: 332-40.
20. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Embo J 2003; 22: 2411-21.
21. Tanaka Y, Miyamoto S, Suzuki SO et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005; 11: 4783-92.
22. Peschon JJ, Slack JL, Reddy P et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281-4.
23. Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993; 73: 249-61.
24. Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995; 269: 230-4.
25. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
26. Cai YC, Jiang Z, Vittimberga F et al. Expression of transforming growth factor-alpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch 1999; 435: 112-15.
27. Lopes LF, Bacchi CE. EGFR and gastrointestinal stromal tumor. an immunohistochemical and FISH study of 82 cases. Mod Pathol 2007; 20: 990-4.
28. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
29. Prenzel N, Zwick E, Daub H et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-8.
30. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol 1992; 118: 741-51.
31. Funatomi H, Itakura J, Ishiwata T et al. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 1997; 72: 512-17.
32. Castillo J, Erroba E, Perugorria MJ et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006; 66: 6129-38.
33. Inui Y, Higashiyama S, Kawata S et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994; 107: 1799-804.
34. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994; 202: 1705-9.
35. Ito Y, Higashiyama S, Takeda T, Okada M, Matsuura N. Bimodal expression of heparin-binding EGF-like growth factor in colonic neoplasms. Anticancer Res 2001; 21: 1391-4.
36. Plowman GD, Green JM, McDonald VL et al. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1990; 10: 1969-81.
37. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997; 70: 722-6.
38. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. Embo J 2003; 22: 1114-24.
39. Kodama T, Ikeda E, Okada A et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004; 165: 1743-53.
40. Grant GM, Cobb JK, Castillo B, Klebe RJ. Regulation of matrix metalloproteinases following cellular transformation. J Cell Physiol 1996; 167: 177-83.
41. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 1996; 39: 444-8.
42. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998; 153: 429-37.
43. Nakada M, Nakamura H, Ikeda E et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999; 154: 417-28.
44. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR, Freeman MR. Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 1999; 140: 5866-75.
45. Aoki M, Nabeshima K, Koga K et al. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Laboratory Invest 2007; 87: 767-79.
46. Patel NV, Acarregui MJ, Snyder JM, Klein JM, Sliwkowski MX, Kern JA. Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. Am J Respir Cell Mol Biol 2000; 22: 432-40.